# 42 U.S.C. 1320f-3 Negotiation and renegotiation process

42 U.S.C. 1320f-3 Negotiation and renegotiation process, “Negotiation and renegotiation process”, is a U.S. Code section of [Part E—Price Negotiation Program to Lower Prices for Certain High-Priced Single Source Drugs](https://ontology.bommaritollc.com/id/01a0f07c-d374-7601-95ff-719446e7acd3); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81ef2c9ff35>

Within: [Title 42—The Public Health and Welfare](https://ontology.bommaritollc.com/id/01a0f07c-d251-723d-b1d9-a44e9ccd25c7) › [Chapter 7—Social Security](https://ontology.bommaritollc.com/id/01a0f07c-d363-76d2-9057-fafa67260f8f) › [Subchapter XI—General Provisions, Peer Review, and Administrative Simplification](https://ontology.bommaritollc.com/id/01a0f07c-d370-70d9-96bf-bed2d7781bae) › [Part E—Price Negotiation Program to Lower Prices for Certain High-Priced Single Source Drugs](https://ontology.bommaritollc.com/id/01a0f07c-d374-7601-95ff-719446e7acd3)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 42 U.S.C. 1320f-3](https://ontology.bommaritollc.com/id/01a0f07c-e07f-772e-a03f-4a5cd2d3808f)
- `eli:cites`:
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [38 U.S.C. 8126 Limitation on prices of drugs procured by Department and certain other Federal agencies](https://ontology.bommaritollc.com/id/01a0f079-e9dd-76db-9b64-ed26ce1d3c86)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
  - [42 U.S.C. 1320f-1 Selection of negotiation-eligible drugs as selected drugs](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d)
  - [42 U.S.C. 1320f-2 Manufacturer agreements](https://ontology.bommaritollc.com/id/01a0f07c-e07d-77db-b182-99a3e31d0c5d)
  - [42 U.S.C. 1395w-3a Use of average sales price payment methodology](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac)
  - [42 U.S.C. 1395w-102 Prescription drug benefits](https://ontology.bommaritollc.com/id/01a0f07c-e11a-725c-9f6d-0bce71771fe1)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title42/USCODE-2024-title42-chap7-subchapXI-partE-sec1320f-3](https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81daffbb2b8)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f07d-0612-72c4-88b7-3b57e8a26d25)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-5304-765f-b848-9952e921211e)
  - [evidence from https://www.govinfo.gov/link/uscode/42/1320f-3?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f16-17dd-7605-8b2a-d5be139b69ae)
- `schema:isPartOf`: [Part E—Price Negotiation Program to Lower Prices for Certain High-Priced Single Source Drugs](https://ontology.bommaritollc.com/id/01a0f07c-d374-7601-95ff-719446e7acd3)
- `schema:legislationIdentifier`: 42 U.S.C. 1320f-3
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Negotiation and renegotiation process
- `schema:url`: [https://www.govinfo.gov/link/uscode/42/1320f-3?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/42/1320f-3?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 42 U.S.C. 1320f-3 Negotiation and renegotiation process

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/42/1320f-3?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title42/USCODE-2024-title42-chap7-subchapXI-partE-sec1320f-3) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (7; `eli:cites`):
  - [42 U.S.C. 1320f Establishment of program](https://ontology.bommaritollc.com/id/01a0f07c-e07b-7379-87a5-77617d9e2ec8)
  - [42 U.S.C. 1320f-1 Selection of negotiation-eligible drugs as selected drugs](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d)
  - [42 U.S.C. 1320f-2 Manufacturer agreements](https://ontology.bommaritollc.com/id/01a0f07c-e07d-77db-b182-99a3e31d0c5d)
  - [42 U.S.C. 1320f-4 Publication of maximum fair prices](https://ontology.bommaritollc.com/id/01a0f07c-e07f-772e-a03f-4a5ee3170754)
  - [42 U.S.C. 1320f-5 Administrative duties and compliance monitoring](https://ontology.bommaritollc.com/id/01a0f07c-e080-7172-9a8d-670b7a61671b)
  - [42 U.S.C. 1320f-7 Limitation on administrative and judicial review](https://ontology.bommaritollc.com/id/01a0f07c-e082-718b-a376-5b225c638b9b)
  - [42 U.S.C. 1395w-112 Requirements for and contracts with prescription drug plan (PDP) sponsors](https://ontology.bommaritollc.com/id/01a0f07c-e11e-77da-b0d1-e2708fd875d3)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 117-169](https://ontology.bommaritollc.com/id/01a0edf4-a81c-717e-8db0-57c66c114e6c)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81ef2c9ff35.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81ef2c9ff35.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81ef2c9ff35.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81ef2c9ff35)
Cite as: 42 U.S.C. 1320f-3 Negotiation and renegotiation process. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81ef2c9ff35
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
